Hemoperfusion during coronary angioplasty: first European experience with a new hemoperfusion pump.
Hemolysis tests with fresh human blood were performed in vitro with a new 5 ml, piston-type hemoperfusion pump, designed to prevent myocardial ischemia during coronary angioplasty. Despite driving pressures greater than 3 atmospheres, shear stress greater than 200 Pa, turbulent pump flow, and the presence of occlusive valves, hemolysis proved to be minimal. This effect is explained by the short amount of time that blood is subjected to mechanical forces that cause hemolysis in the system and by the small volumes of blood involved. During clinical application of the system, angina pectoris, electrocardiographic changes, and systemic blood pressure were used as parameters for myocardial ischemia. There was an effective reduction of ischemia during prolonged (10 min) balloon inflation, demonstrated by the absence of angina, minimal electrocardiographic changes, and normal blood pressure. In addition, the system proved to be safe and effective during high-risk angioplasty.